Evaluation of D-Fi for the Treatment of Wounds Due to DEB

Running, not enrolling · Phase 3

Conditions studied: Dystrophic Epidermolysis Bullosa

In brief

The purpose of this study is to determine whether administration of D-Fi in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Dystrophic Epidermolysis Bullosa.

Key facts

Study ID

NCT06892639

Run by

Castle Creek Biosciences, LLC.

People needed

32

Starts

2025-03-27

Expected to finish

2042-02-01

Last updated by the study team

2026-03-13

Who can join

Age: 2 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female ≥2 years of age at the Screening visit
• Clinical diagnosis of DEB with confirmation of COL7A1 genetic mutation.

You may not qualify if…

• Medical instability limiting ability to travel to the investigative site.
• Active infection with human immunodeficiency virus, hepatitis B or hepatitis C.
• The presence of clinically significant COL7 antibodies.
• Evidence of systemic infection.
• Known allergy to any of the constituents of the product.
• Female who is pregnant or breastfeeding.

Where it is running

• Stanford University School of Medicine, Dermatology — Redwood City, California, United States
• Mission Dermatology — Santa Margarita, California, United States
• Children's Hospital Colorado — Aurora, Colorado, United States
• University of Massachusetts — Worcester, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.